NEWS
-
Harry Hoffman and David Herbert join the HM Venture Partners team as Venture Partners
, May 7, 2024
Sagimet Biosciences Announces Positive Results from Phase 2b Clinical Trial , January 22, 2024
Osteal Therapeutics’ VT-X7 Receives FDA’s Breakthrough Therapy Designation for the treatment of periprosthetic joint infection , December 5, 2023
Novo Nordisk Buys Hypertension Company, KBP, in $1.3 Billion Deal, October 16, 2023
Osteal Therapeutics Closes $23M Series C Financing, September 21, 2023
Laborie Medical Technologies Announces Agreement to Acquire Urotronic for up to $600 Million, September 06, 2023
Urotronic Announces FDA Approval of Optilume® BPH Catheter System, Pioneering the Next Generation of Minimally Invasive Solutions for Enlarged Prostate Symptom Relief, July 11, 2023
OncoC4 - BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications (oncoc4.com), March 20, 2023
GIE Medical Launches Two Clinical Trials to Investigate Use (globenewswire.com), December 13, 2022
APEX phase 2 clinical trial | Osteal Therapeutics (ostealtx.com), November 04, 2022
Sagimet Biosciences Announces Positive Interim Phase 2b Clinical Trial Data with Denifanstat (TVB-2640), a First-in-Class Fatty Acid Synthase Inhibitor, in Moderate-to-Severe Non-alcoholic Steatohepatitis (NASH) Patients (sagimet.com), November 03, 2022
Laborie Medical Technologies Acquires Exclusive License to Optilume® (laborie.com), January 05, 2022
FDA Approves Optilume® Urethral Drug Coated Balloon, a breakthrough treatment for urethral strictures (prnewswire.com), December 13, 2021
Merck to Acquire OncoImmune (merck.com), November 23, 2020
Mayo Clinic Signs Joint Venture Agreement with Hillhouse Capital Group (Mayo Clinic News Network), January 15, 2015